<DOC>
	<DOCNO>NCT02103361</DOCNO>
	<brief_summary>The purpose OTIS Autoimmune Diseases Pregnancy Study monitor plan unplanned pregnancy expose certain medication , evaluate possible teratogenic effect medication follow live born infant one year birth . With respect fetal outcome , important evaluate spectrum outcome may relevant medication exposure pregnancy , include easily recognizable defect visible birth , well subtle delay defect may readily identifiable without special expertise observation beyond newborn period .</brief_summary>
	<brief_title>Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases Pregnancy Project</brief_title>
	<detailed_description>The purpose Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases Pregnancy Project follow pregnant woman woman deliver baby , treat Stelara within 3 month last menstrual period ( LMP ) pregnancy evaluate possible effect medication pregnancy outcome include child development growth one year age .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Documentation exposure Stelara ( ustekinumab ) pregnancy within 3 month prior first day last menstrual period ( LMP ) number day , time , dose , time completion pregnancy . Documentation gestational timing exposure Stelara ( ustekinumab ) Women exposure Stelara ( ustekinumab ) pregnancy .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>autoimmune disease</keyword>
	<keyword>pregnancy</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Stelara</keyword>
	<keyword>ustekinumab</keyword>
	<keyword>birth outcome</keyword>
	<keyword>malformation</keyword>
	<keyword>birth defect</keyword>
	<keyword>psoriatic arthritis</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>